Success Metrics

Clinical Success Rate
100.0%

Based on 38 completed trials

Completion Rate
100%(38/38)
Active Trials
0(0%)
Results Posted
18%(7 trials)

Phase Distribution

Ph phase_2
1
3%
Ph phase_4
13
34%
Ph phase_3
19
50%

Phase Distribution

0

Early Stage

1

Mid Stage

32

Late Stage

Phase Distribution33 total trials
Phase 2Efficacy & side effects
1(3.0%)
Phase 3Large-scale testing
19(57.6%)
Phase 4Post-market surveillance
13(39.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

38 of 38 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

38

all time

Status Distribution
Completed(38)

Detailed Status

Completed38

Development Timeline

Analytics

Development Status

Total Trials
38
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (3.0%)
Phase 319 (57.6%)
Phase 413 (39.4%)

Trials by Status

completed38100%

Recent Activity

0 active trials
Showing 5 of 38
completedphase_4

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

NCT00101751
completedphase_3

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

NCT00476437
completedphase_3

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

NCT02762578
completedphase_3

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

NCT02648217
completed

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

NCT00659282
View all 38 trials

Clinical Trials (38)

Showing 20 of 38 trialsScroll for more
NCT00101751Phase 4

INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

Completed
NCT00476437Phase 3

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Completed
NCT02762578Phase 3

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

Completed
NCT02648217Phase 3

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Completed
NCT00659282

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

Completed
NCT00605020Phase 3

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Completed
NCT00613951Phase 2

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Completed
NCT00184600Phase 3

Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes

Completed
NCT00564668Phase 3

Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes

Completed
NCT00617565Phase 3

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Completed
NCT01704378Phase 4

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Completed
NCT00592969Phase 4

Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

Completed
NCT00184626Phase 4

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Completed
NCT01467401Phase 4

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Completed
NCT01467375Phase 3

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Completed
NCT00469092Phase 4

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Completed
NCT00869908

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication

Completed
NCT00097877Phase 3

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Completed
NCT00097279Phase 3

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

Completed
NCT00605111Phase 4

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Completed

Drug Details

Intervention Type
DRUG
Total Trials
38